Latest News

The new indication is for those aged 12 years and older with unresectable or metastatic SS who received prior chemotherapy and are positive for certain genetic subtypes.

On GLP-1s like semaglutide or tirzepatide, weight loss can mean muscle loss; encourage patients to use protein and resistance training to stay strong.

Understanding this rapidly evolving therapeutic landscape will be essential as obesity pharmacotherapy continues to transform diabetes and cardiometabolic care.

Incorporate important health screenings and lifestyle prevention tips in MTM consults.

From AI-driven dispensing to grassroots advocacy wins, here are the key insights Pharmacy Times gathered at McKesson ideaShare 2026 in Denver.

Specialty dispensing and infusion services offer real opportunity—but the path requires careful planning, sequencing, and the right resources.

Single-cell findings presented at EHA 2026 identify B cells as potential drivers of immune dysregulation in acquired hemophilia A.

Ammoxetine is a novel SNRI derived from duloxetine, exhibiting a 3- to 10-fold greater potency.

Leonard Egede explains why PHQ-9 screening belongs in every cardio-kidney-metabolic (CKM) syndrome risk assessment—and how community pharmacists can reach patients the formal system misses.

Pharmacists cut through probiotic hype by matching strains and doses to evidence, checking shelf-life potency, and navigating confusing regulations.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Human connection is often the first casualty of rising prescription counts and constant interruptions.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Three finalist pharmacies shared the mindsets, tools, and community-rooted strategies driving their operational success and patient-centered care.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Oncology pharmacists step into precision care—tracking mRNA vaccines, frailty-guided supportive therapy, NGS actionability, and new thoracic targets.

Two pharmacy owners share real-world strategies for integrating artificial intelligence (AI) and automation to boost efficiency, expand clinical capacity, and elevate patient care.

New GI cancer data highlight emerging targeted therapies, ctDNA-guided surveillance, and pharmacist-led workflows to boost outcomes.